MHMichiel S. van der Heijden

Michiel S. van der Heijden

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michiel S. van der Heijden has a total of 674 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Relationship Between Pre‐Operative Ipilimumab and Nivolumab Pharmacokinetics and Treatment Outcome in Locoregionally Advanced Urothelial Cancer

    by Sybrand W. J. Zielhuis, Karen A. M. de Jong, Hinke Huisman‐Siebinga, Lisa T. van der Heijden, Bart A. W. Jacobs, Jos H. Beijnen, Hilde Rosing, Chantal F. Stockem, Jeroen van Dorp, Michiel S. van der Heijden, et al.

    Patients with locoregionally advanced urothelial cancer (UC) received three pre‐operative cycles of ipilimumab and nivolumab in the NABUCCO trial, across three cohorts with different dosing combinations. This study aimed to define the pharmacokinetics (PK) of both drugs in this population and to assess the relationship between the PK and treatment response. Ipilimumab and nivolumab serum concentrations were measured in 139 samples of 52 patients. A population PK model was developed for both drugs using nonlinear mixed‐effects modeling. This model was used to examine baseline clearance (CL 0 )– and exposure‐response relationships, with pathological response at surgery as efficacy parameter. A logistic regression model was constructed to quantify these relationships. The developed population PK model adequately described ipilimumab and nivolumab observations. Individual CL 0 estimates of both drugs were correlated (correlation coefficient = 0.57). Among patients in the lowest quartile of CL 0 of both drugs, twelve out of thirteen patients were responders. In the logistic regression model, a relatively low nivolumab CL 0 and high ipilimumab exposure were successfully related to treatment response. The model predicted probability of response was higher for high‐dose ipilimumab (3 mg/kg) compared to low‐dose ipilimumab (1 mg/kg) (54% vs. 29%, respectively), and was in line with NABUCCO trial outcomes. These results support the hypothesis that for ipilimumab, an exposure‐response relationship exists, while this is not the case for nivolumab. Further confirmation of these relationships is warranted, given the limited number of patients included in the analysis.

  • Preexisting Immunity and hrHPV Status Determine Immunotherapy Response in Advanced Penile Cancer: Biomarkers and Overall Survival in the PERICLES Trial

    by Tynisha S. Rafael, Alberto Gil-Jimenez, Laura Elst, Hielke M. de Vries, Iris M. Seignette, Elise Bekers, Marta Lopez-Yurda, Dennis Peters, Marja Nieuwland, Erik Hooijberg, et al.

    Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy (RT) in advanced penile cancer. Here, we report mature overall survival (OS) and updated progression-free survival (PFS) outcomes and an in-depth biomarker analysis. Patients were treated with atezolizumab monotherapy (n = 12) or atezolizumab in combination with RT (n = 20, 33 fractions of 1.5–1.8 Gy) for locoregional disease control. Comprehensive analysis of baseline tumor tissue (n = 28/31) was performed using bulk RNA sequencing, immunohistochemistry, and multiplex immunofluorescence. Additionally, spatial transcriptomics (n = 9) was conducted to further explore functionality and (co-)localization of immune cell subsets. With extended follow-up (median: 38 months), landmark 2-year OS and PFS in the full study cohort was 18.8% [95% confidence interval (CI), 9.1–38.6] and 12.5% (95% CI, 5–31.3), respectively. High-risk human papillomavirus (hrHPV)-positive tumors were enriched for IFNγ and IFNα signatures, potentially explaining the improved PFS and OS observed in this subgroup. Both stromal CD68+ myeloid cell density and intratumoral CD8+PD-1+ T-cell density were associated with nonprogression at 1 year. Increased intratumoral CD8+PD-1+ T-cell density was also associated with improved PFS and OS, with consistent findings in the hrHPV-positive subgroup. Spatial transcriptomics identified these CD8+ T cells as tissue-resident cytotoxic effector cells coexpressing checkpoint molecules (LAG3 and TIGIT), chemokines (CCL4 and CXCL13), and cytotoxic molecules (PRF1 and GZMB). Interrogation of the penile cancer immune microenvironment highlights CD8+PD-1+ T cells as candidate biomarkers in relation to clinical benefit from immune checkpoint blockade in advanced PeSCC.

  • Gemcitabine Intravesical Drug-Releasing System in Bacillus Calmette-Guérin–Unresponsive Papillary-Only High-Risk Non–Muscle-Invasive Bladder Cancer: 12-Month Update From SunRISe-1 Cohort 4

    by Siamak Daneshmand, Michiel S. Van der Heijden, David Cahn, Eugene B. Cone, Laurence Belkoff, Daniel Zainfeld, Won Kim, Shalaka Hampras, Jason Martin, Abhijit Shukla, et al.

    Purpose: Patients with bacillus Calmette-Guérin (BCG)–unresponsive papillary-only high-risk non–muscle-invasive bladder cancer (HR NMIBC) have limited bladder-sparing treatment options; radical cystectomy (RC) is the standard of care despite significant morbidity and mortality risks. We report efficacy and safety of the gemcitabine intravesical drug-releasing system (gem-iDRS) in patients with BCG-unresponsive papillary-only HR NMIBC enrolled in Cohort 4 of the phase IIb SunRISe-1 study (ClinicalTrials.gov identifier: NCT04640623 ). Methods: Patients received gem-iDRS every 3 weeks through month 6 and then every 12 weeks through month 24. The primary end point was disease-free survival (DFS). Results: Fifty-two patients were treated. At clinical cutoff (July 3, 2025), the median follow-up was 15.9 months. The 12-month DFS rate was 76.0% (95% CI, 60.8 to 86.0), with comparable efficacy in high-grade Ta and T1 disease. The 12-month overall survival and RC-free rates were 98.0% (95% CI, 86.6 to 99.7) and 93.8% (95% CI, 81.9 to 97.9), respectively. The progression-free survival at 12 months was 95.6% (95% CI, 83.5 to 98.9) in a post hoc analysis. Grade ≥3 treatment-related adverse events occurred in 13.5% of patients, most commonly bladder pain (3.8%). Patient-reported quality of life remained stable throughout treatment. Conclusion: Gem-iDRS demonstrated high efficacy, a favorable benefit-risk profile, supporting its investigation as a potential bladder-sparing treatment option for BCG-unresponsive papillary-only HR NMIBC.

  • Open Access

    Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial

    by Sarah M. H. Einerhand, Hamza Ali, Stephen Q. Wong, Jeroen van Dorp, Tatum van Maanen, Jeantine M. de Feijter, Maurits L. van Montfoort, Thierry N. Boellaard, Linde M. Braaf, Wim Brugman, et al.

    New therapeutic strategies for patients with therapy-refractory metastatic urothelial carcinoma (mUC) are still needed. In the phase I-II ICRA trial, a multicenter, open-label, phase Ib-II clinical trial (NCT03871036), we evaluated whether paclitaxel plus tremelimumab, with or without durvalumab, could induce a tumor response in mUC following platinum chemotherapy and immune checkpoint inhibition (ICI). Patients were randomized between three arms: A (n = 20) paclitaxel plus T750mg; B (n = 12) paclitaxel plus T300mg plus D1500mg; C (n = 12) T750mg. The primary outcome, objective response rate, was met with 26% in arm A (88% CI = [14,36%]) versus 17% (88% CI = [3,42%]) in arm B and 8% (88% CI = [0.3,33%]) in arm C. Secondary outcomes included safety, duration of response and survival. Grade 3-4 treatment-related adverse events occurred in (A) 45%, (B) 75%, and (C) 25% of patients. Murine experiments showed attenuated tumor outgrowth for paclitaxel plus anti-CTLA-4 compared to monotherapy with either agent. Transcriptomic analyses showed upregulation of inflammation signatures in on-treatment tumor tissue biopsies. This study demonstrated encouraging antitumor activity in therapy-refractory mUC treated with paclitaxel plus high-dose anti-CTLA-4 and suggests immune induction may still be possible after failure to anti-PD-(L)1 therapy.

  • Top Cited Papers

    Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial

    by Jan-Jaap J. Mellema, Chantal F. Stockem, Cameron Herberts, Samantha K. Cheung, Daniel J. Vis, Bas W. G. van Rhijn, Laura S. Mertens, Thierry N. Boellaard, Maurits L. van Montfoort, Sara Balduzzi, et al.

    Radical cystectomy is the most commonly used definitive local treatment for muscle-invasive bladder cancer (MIBC), yet it carries substantial perioperative complication risk, alongside major changes in urinary and sexual function. Chemoradiotherapy (CRT) is used as a bladder-sparing alternative but is usually reserved for small, solitary tumors. Highly active systemic induction therapy could enable bladder preservation for patients with more advanced tumors and reduce recurrence risk. We previously demonstrated high activity of preoperative ipilimumab (3 mg kg−1) plus nivolumab in patients with stage III MIBC. Given this high activity, the single-arm, multicenter phase 2 INDIBLADE trial aimed to provide effective bladder-sparing treatment to patients with stage II/III (cT2-4aN0-2, n = 50) MIBC, using induction ipilimumab (3 mg kg−1) plus nivolumab followed by CRT. After a median follow-up of 28.7 months, the primary endpoint of estimated 2-year bladder-intact event-free survival (BI-EFS) was met at 78% (95% confidence interval (CI): 0.67−0.9, P < 0.001). Secondary endpoints included overall survival, safety and the predictive value of circulating tumor DNA (ctDNA). Two-year overall survival was 96% (95% CI: 0.91−1). Grade 3−4 immune-related adverse events occurred in 24% of patients; grade 3−4 CRT-related adverse events occurred in 7% of patients. Absence of detectable ctDNA after induction immunotherapy was associated with BI-EFS (hazard ratio 8.3, 95% CI: 1.38−50.36, P = 0.02). In conclusion, our results show that induction combination immunotherapy followed by CRT is an effective bladder-sparing treatment in MIBC, and response can be monitored by ctDNA. ClinicalTrials.gov identifier: NCT05200988.


  • Open Access

    Systemic therapy for urothelial cancer: platinum defeated?

    by Chantal F. Stockem, Michiel S. van der Heijden

    Platinum-based chemotherapy was the mainstay of treatment for advanced urothelial carcinoma (UC) for decades, but the therapeutic landscape has fundamentally changed. Immune checkpoint blockade showed overall survival (OS) benefit in phase 3 trials: as second line (pembrolizumab), as maintenance therapy (avelumab) following frontline chemotherapy response, or in combination with cisplatin-chemotherapy (nivolumab). Options after failure to chemo- and immunotherapy consist of enfortumab vedotin (EV) or erdafitinib (in case of FGFR3 mutations). However, the most significant change was the superiority of EV plus pembrolizumab over chemotherapy in the EV302 trial, which has become the new standard frontline therapy. In the peri-operative setting, anti-PD-(L)1 has shown benefit as adjuvant therapy (nivolumab and pembrolizumab; not yet for OS) and in the peri-operative setting, combined with chemotherapy (durvalumab; including OS).

  • Open Access

    Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

    by Rana R. McKay, Sumanta Pal, Wanling Xie, David Aggen, Laurence Albiges, Andrea Apolo, Michael B. Atkins, Rick Bangs, Kathryn E. Beckermann, Joaquim Bellmunt, et al.

    The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequencing. The 2025 Advanced Urologic Cancer Consensus Conference was convened to establish evidence‐based expert consensus recommendations for optimal management. A multidisciplinary panel of 51 experts participated in a modified Delphi process addressing questions developed through iterative consensus‐building covering RCC and UTC management. Voting occurred before and after the conference, and analyses focused on postmeeting responses. Consensus was defined as ≥75% agreement, with strong consensus as >90%. Strong consensus was found on the use of adjuvant pembrolizumab for higher risk RCC (pathologic T2 [pT2], grade 4; pT3–pT4, any grade; pTXN1; or fully resected metastatic disease) and on neoadjuvant therapy before cystectomy for localized UTC. There was strong consensus on the use of enfortumab vedotin plus pembrolizumab as frontline therapy for metastatic UTC and the use of platinum‐based chemotherapy postprogression in biomarker‐negative UTC. For RCC, there was consensus on the role of single‐agent vascular endothelial growth factor receptor–tyrosine kinase inhibitor therapy after progression on frontline immune checkpoint inhibitor/vascular endothelial growth factor receptor–tyrosine kinase inhibitor therapy or dual immune checkpoint inhibitor therapy. However, there was a lack of consensus on other critical areas in the management of RCC and UTC. The 2025 Advanced Urologic Cancer Consensus Conference provides evidence‐informed guidance for complex clinical scenarios while identifying critical research priorities. The group recognizes that the lack of consensus across multiple areas highlights the need for improved patient selection and prospective studies enabling optimal combination and sequencing approaches. This iterative annual process will address evolving treatment paradigms to optimize outcomes.


  • Top Cited Papers
    Open Access

    TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study

    by Siamak Daneshmand, Michiel S. Van der Heijden, Joseph M. Jacob, Felix Guerrero-Ramos, Martin Bögemann, Giuseppe Simone, Christopher M. Pieczonka, Nelson Canales Casco, Daniel Zainfeld, Philipp Spiegelhalder, et al.

    PURPOSE: TAR-200 is a first-in-class intravesical drug-releasing system designed to provide sustained delivery of gemcitabine in the bladder. TAR-200 alone or in combination with cetrelimab (PD-1 inhibitor) could improve outcomes in patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC) ineligible for or refusing radical cystectomy. METHODS: In this phase IIb parallel cohort study, patients with BCG-unresponsive carcinoma in situ (CIS) with/without papillary disease received TAR-200 monotherapy (Cohort 2 [C2]), TAR-200 plus cetrelimab (C1), or cetrelimab monotherapy (C3). Patients with BCG-unresponsive high-risk papillary disease–only NMIBC received TAR-200 monotherapy (C4). TAR-200 was dosed through month 24 and cetrelimab through month 18. Primary end points were centrally confirmed overall complete response (CR) rate (C1-3) or disease-free survival (DFS) rate (C4) (ClinicalTrials.gov number: NCT04640623 ). RESULTS: At data cutoff (March 31, 2025), 53, 85, 28, and 52 patients were treated in C1-4, respectively. In C2, CR rate and median duration of response were 82.4% (95% CI, 72.6 to 89.8) and 25.8 months (95% CI, 8.3 to not estimable), respectively. In C4, 6-, 9-, and 12-month DFS rates were 85.3% (95% CI, 71.6 to 92.7), 81.1% (95% CI, 66.7 to 89.7), and 70.2% (95% CI, 51.6 to 82.8), respectively. In C1 and C3, CR rates were 67.9% (95% CI, 53.7 to 80.1) and 46.4% (95% CI, 27.5 to 66.1), respectively. Rates of grade ≥3 treatment-related adverse events (AEs) were 12.9%, 13.5%, 37.7%, and 7.1% in C2, C4, C1, and C3, respectively, and of serious treatment-related AEs, 5.9%, 5.8%, 15.1%, and 3.6%. No treatment-related deaths occurred. CONCLUSION: TAR-200 monotherapy was well tolerated, with a high CR rate, durable responses, and prolonged DFS in patients with BCG-unresponsive high-risk NMIBC. TAR-200 monotherapy offered a more favorable risk-benefit profile versus TAR-200 plus cetrelimab or cetrelimab alone in BCG-unresponsive CIS.